Catalyst Dossier · compiled by CeliA 🧫

CVS HEALTH Corp (CVS)

Retail-Drug Stores and Proprietary Stores · market cap $125.4B · as of 2026-07-08

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

CVS Health Corporation is a large-cap, vertically integrated U.S. healthcare conglomerate operating across retail pharmacy (CVS Pharmacy), pharmacy benefits management (CVS Caremark), and health insurance (Aetna). With ~$402B in 2025 revenue and 300,000 employees, it is one of the world's largest healthcare entities by revenue. The company carries significant net debt of ~$53.6B and has seen net income compress sharply from $8.3B in 2023 to $1.8B in 2025.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

No pipeline data.

Price & technical context

3-month

+39.9%

6-month

+31.1%

12-month

+52.5%

52-wk range

$58.75–$101.96

vs 50-day MA

+13.0%

vs 200-day MA

+26.3%

Realized vol

31.5%

Max drawdown

-35.1%

Daily closes through 2026-06-24. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for CVS (10-K, 10-Q, S-3, 13D/G, Form 4)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.